1. Home
  2. TYG vs CDNA Comparison

TYG vs CDNA Comparison

Compare TYG & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tortoise Energy Infrastructure Corporation

TYG

Tortoise Energy Infrastructure Corporation

HOLD

Current Price

$46.04

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$21.74

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYG
CDNA
Founded
2003
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2003
2007

Fundamental Metrics

Financial Performance
Metric
TYG
CDNA
Price
$46.04
$21.74
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$28.00
AVG Volume (30 Days)
150.3K
652.5K
Earning Date
05-04-2026
04-28-2026
Dividend Yield
11.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
N/A
$48,324,000.00
Revenue This Year
N/A
$16.01
Revenue Next Year
N/A
$11.31
P/E Ratio
$52.62
$429.80
Revenue Growth
N/A
18.93
52 Week Low
$40.01
$10.96
52 Week High
$51.18
$23.24

Technical Indicators

Market Signals
Indicator
TYG
CDNA
Relative Strength Index (RSI) 40.23 59.06
Support Level $45.32 $15.80
Resistance Level $50.87 $22.89
Average True Range (ATR) 0.92 1.00
MACD -0.14 -0.06
Stochastic Oscillator 19.92 76.54

Price Performance

Historical Comparison
TYG
CDNA

About TYG Tortoise Energy Infrastructure Corporation

Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: